ATE283268T1 - 2-adamantylethylamine und deren verwendung bei der behandlung von abnormalitäten in der glutamat transmission - Google Patents

2-adamantylethylamine und deren verwendung bei der behandlung von abnormalitäten in der glutamat transmission

Info

Publication number: ATE283268T1
Authority: AT; Austria
Prior art keywords: abnormalities; aryl; alkyl; aromatic heterocyclic; adamantylethylamines
Prior art date: 2000-07-25

Application number

AT01951817T

Other languages

English (en)

Inventor

Michael Frederick Snape

Roger John Gillespie

Claire Elizabeth Dawson

Steven Michael Mcateer

Suneel Gaur

Original Assignee

Vernalis Res Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-07-25

Filing date

2001-07-25

Publication date

2004-12-15

2001-07-25 Application filed by Vernalis Res Ltd filed Critical Vernalis Res Ltd

2004-12-15 Application granted granted Critical

2004-12-15 Publication of ATE283268T1 publication Critical patent/ATE283268T1/de

Links

WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 title 1
230000005540 biological transmission Effects 0.000 title 1
229930195712 glutamate Natural products 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 3
125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 3
125000003118 aryl group Chemical group 0.000 abstract 3
229910052739 hydrogen Inorganic materials 0.000 abstract 2
239000001257 hydrogen Substances 0.000 abstract 2
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
230000005856 abnormality Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
229910052736 halogen Inorganic materials 0.000 abstract 1
150000002367 halogens Chemical class 0.000 abstract 1
125000005842 heteroatom Chemical group 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
125000001424 substituent group Chemical group 0.000 abstract 1
230000024587 synaptic transmission, glutamatergic Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/16—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings
- C07C211/19—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings containing condensed ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Psychology (AREA)
Virology (AREA)
Hematology (AREA)
Communicable Diseases (AREA)
Anesthesiology (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Addiction (AREA)
Molecular Biology (AREA)
Hospice & Palliative Care (AREA)

AT01951817T 2000-07-25 2001-07-25 2-adamantylethylamine und deren verwendung bei der behandlung von abnormalitäten in der glutamat transmission ATE283268T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0018272.5A GB0018272D0 (en)	2000-07-25	2000-07-25	Chemical compounds IV
PCT/GB2001/003321 WO2002008219A2 (en)	2000-07-25	2001-07-25	2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission

Publications (1)

Publication Number	Publication Date
ATE283268T1 true ATE283268T1 (de)	2004-12-15

Family

ID=9896338

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01951817T ATE283268T1 (de)	2000-07-25	2001-07-25	2-adamantylethylamine und deren verwendung bei der behandlung von abnormalitäten in der glutamat transmission

Country Status (10)

Country	Link
US (1)	US6828318B2 (de)
EP (1)	EP1305306B1 (de)
JP (1)	JP2004504395A (de)
AT (1)	ATE283268T1 (de)
AU (1)	AU2001272666A1 (de)
CA (1)	CA2415585A1 (de)
DE (1)	DE60107435T2 (de)
ES (1)	ES2233664T3 (de)
GB (1)	GB0018272D0 (de)
WO (1)	WO2002008219A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200403066A (en) *	2002-04-30	2004-03-01	Novartis Ag	New uses of substituted aminoalkanephosphonic acids
WO2004034963A2 (en) *	2002-05-17	2004-04-29	Eisai Co., Ltd.	Methods and compositions using cholinesterase inhibitors
US20050113458A1 (en) *	2003-10-22	2005-05-26	Forest Laboratories, Inc.	Use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic a-beta peptides in amyloidopathies
TW200531680A (en) *	2004-03-03	2005-10-01	Merz Pharma Gmbh & Co Kgaa	Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
EP1820792B1 (de) *	2006-02-21	2012-01-18	Hexal AG	Verfahren zur Herstellung von Adamantanaminen
WO2008035049A1 (en) *	2006-09-18	2008-03-27	Merz Pharma Gmbh & Co. Kgaa	Adamantanyl-(cyclopropyl)-ketones as metabotropic glutamate receptor modulators
KR101769999B1 (ko)	2008-09-18	2017-08-21	노오쓰웨스턴 유니버시티	Ｎｍｄａ 수용체 조절제 및 그의 용도
US8951968B2 (en)	2009-10-05	2015-02-10	Northwestern University	Methods of treating depression and other related diseases
PL2578212T3 (pl)	2010-05-24	2017-01-31	Farmalider Sa	Związek hamujący aktywację enzymu Erk 1/2 do zastosowania w leczeniu chorób neurodegeneracyjnych
SG194230A1 (en) *	2011-04-27	2013-12-30	Univ Northwestern	Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders
JP6531042B2 (ja)	2013-01-29	2019-06-12	アプティニックスインコーポレイテッド	スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
MX2015009773A (es)	2013-01-29	2016-08-05	Aptinyx Inc	Moduladores de receptores nmda de espiro-lactama y sus usos.
CA2899010A1 (en)	2013-01-29	2014-08-07	Naurex, Inc.	Spiro-lactam nmda receptor modulators and uses thereof
PE20151436A1 (es)	2013-01-29	2015-10-10	Naurex Inc	Moduladores de receptores nmda de espiro-lactama y sus usos
BR112015018087B1 (pt)	2013-01-29	2022-09-20	Aptinyx Inc	Compostos moduladores de receptor n-metil-d-aspartato (nmda) de espiro-lactama, composição farmacêutica e uso dos mesmos
CN104844532A (zh) *	2014-02-19	2015-08-19	周敬业	抗病毒化合物、其制备方法和用途
RU2605698C1 (ru) *	2015-12-23	2016-12-27	Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный технический университет" (ВолгГТУ)	Производные 2-(адамант-2-ил)этиламина, обладающие потенциальной противовирусной активностью
WO2017201285A1 (en)	2016-05-19	2017-11-23	Aptinyx Inc.	Spiro-lactam nmda receptor modulators and uses thereof
PE20190174A1 (es)	2016-05-19	2019-02-01	Aptinyx Inc	Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
CN109661398B (zh)	2016-08-01	2022-07-05	阿普廷伊克斯股份有限公司	螺-内酰胺和二-螺-内酰胺nmda受体调节剂及其用途
SG11201900554YA (en)	2016-08-01	2019-02-27	Aptinyx Inc	Spiro-lactam nmda modulators and methods of using same
US10918637B2 (en)	2016-08-01	2021-02-16	Aptinyx Inc.	Spiro-lactam NMDA receptor modulators and uses thereof
AU2017306152A1 (en)	2016-08-01	2019-01-31	Aptinyx Inc.	Spiro-lactam NMDA receptor modulators and uses thereof
BR112019001921A2 (pt)	2016-08-01	2019-05-14	Aptinyx Inc.	moduladores do receptor nmda de espiro-lactama e seus usos
US11578072B2 (en)	2018-01-31	2023-02-14	Aptinyx Inc.	Spiro-lactam NMDA receptor modulators and uses thereof
US12012413B2 (en)	2019-11-11	2024-06-18	Tenacia Biotechnology (Hong Kong) Co., Limited	Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL6900004A (de) *	1969-01-02	1970-07-06
WO1997023202A1 (en) *	1995-12-22	1997-07-03	STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITYA ND THE UNIVERSITY OF OREGON, EUGENE OREGON	Subtype-selective nmda receptor ligands and the use thereof
WO1999031075A1 (en)	1997-12-16	1999-06-24	Warner-Lambert Company	1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
GB9802225D0 (en) *	1998-02-02	1998-04-01	Cerebrus Ltd	Chemical compounds
GB9901691D0 (en) *	1999-01-26	1999-03-17	Cerebrus Ltd	Chemical compounds

2000
- 2000-07-25 GB GBGB0018272.5A patent/GB0018272D0/en not_active Ceased
2001
- 2001-07-25 JP JP2002514125A patent/JP2004504395A/ja not_active Withdrawn
- 2001-07-25 AU AU2001272666A patent/AU2001272666A1/en not_active Abandoned
- 2001-07-25 WO PCT/GB2001/003321 patent/WO2002008219A2/en not_active Ceased
- 2001-07-25 CA CA002415585A patent/CA2415585A1/en not_active Abandoned
- 2001-07-25 EP EP01951817A patent/EP1305306B1/de not_active Expired - Lifetime
- 2001-07-25 DE DE60107435T patent/DE60107435T2/de not_active Expired - Fee Related
- 2001-07-25 ES ES01951817T patent/ES2233664T3/es not_active Expired - Lifetime
- 2001-07-25 US US10/333,952 patent/US6828318B2/en not_active Expired - Fee Related
- 2001-07-25 AT AT01951817T patent/ATE283268T1/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
DE60107435T2 (de)	2005-12-15
EP1305306B1 (de)	2004-11-24
US6828318B2 (en)	2004-12-07
JP2004504395A (ja)	2004-02-12
DE60107435D1 (de)	2004-12-30
WO2002008219A2 (en)	2002-01-31
GB0018272D0 (en)	2000-09-13
ES2233664T3 (es)	2005-06-16
WO2002008219A3 (en)	2002-06-13
AU2001272666A1 (en)	2002-02-05
US20030207881A1 (en)	2003-11-06
EP1305306A2 (de)	2003-05-02
CA2415585A1 (en)	2002-01-31

Legal Events

Date	Code	Title	Description
2005-05-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE283268T1 (de)	2004-12-15	2-adamantylethylamine und deren verwendung bei der behandlung von abnormalitäten in der glutamat transmission
UY25679A1 (es)	2000-03-31	Derivados de quinolin-2-ona inhibidores de la farnesil proteína transferasa útiles como agentes contra el cáncer
EP0348523A4 (en)	1991-10-09	Thienodiazepine compounds and their medicinal use
ES2181853T3 (es)	2003-03-01	Tratamiento del tinnitus empleando agentes neuroprotectores.
DZ1694A1 (fr)	2002-02-17	"n-(2-Aminoethyl)-benzothialozones".
DK1000034T3 (da)	2003-01-27	Substituerede 6-alkylphenanthridiner
SE8406302D0 (sv)	1984-12-12	New aminoguanidine derivatives and a process for the preparation thereof
ATE242220T1 (de)	2003-06-15	Benzimidazolderivate mit dopaminerger wirkung
DK0783495T3 (da)	2002-04-22	Quinoxalinderivater, der er egnede i terapi
ATE223379T1 (de)	2002-09-15	N-aryloxyethylaminderivate zur behandlung der depression
ES455741A1 (es)	1978-04-16	Un procedimiento para la preparacion de nuevos derivados de 1,3-bencenodimetanol.
ATE137759T1 (de)	1996-05-15	S'-adenosyl-methionin-decarboxylase-inhibitoren
DE60009263D1 (de)	2004-04-29	2-adamantanmethanamin verbindungen zur behandlung von abweichungen bei glutamatergischen übertragungen
DE69808669D1 (de)	2002-11-14	1-(adamantyl)amidine und ihre verwendung bei der behandlung von zuständen, die zusammenhängen mit abweichungen bei glutamatergischen übertragungen
MX9709465A (es)	1998-02-28	Derivados de bencimidazol 2-sustituidos como inhibidores de la proliferacion de celulas del musculo liso.
ES471895A1 (es)	1979-10-01	Procedimiento para preparar derivados de benzamidina
ATE250027T1 (de)	2003-10-15	Azetidincarboxamidderivate zur behandlung von zns-erkrankungen
DE69619088D1 (de)	2002-03-21	Quinoxalin-Derivate zur Behandlung von Tinnitus
KR970706280A (ko)	1997-11-03	5-HT1A 길항제로서의 비사이클릭 카복스아미드(Bicyclic carboxamides as 5-HT1 antagonists)
ATE5144T1 (de)	1983-11-15	Thiazolderivate, ihre herstellung und ihre therapeutische anwendung.
TW429147B (en)	2001-04-11	Pharmaceutical composition for the treatment of CNS disorders
PT1049670E (pt)	2002-12-31	Derivados de azetidinocarboxamida para o tratamento de perturbacoes do snc
NO954764L (no)	1996-01-25	Psoralen-derivater, deres fremstilling og anvendelse
HUP0204144A2 (en)	2003-05-28	N-(1-phenylethyl)-5-phenyl-imidazole-2-amine compounds, their compositions and uses
ATE81466T1 (de)	1992-10-15	Verwendung von 2-oxo-imidazolidin-derivaten zur prophylaxe und zur behandlung von herzinsuffizienz.